8 results about "Mirtazapine" patented technology

This application relates to a method for preparing melitracen hydrochloride intermediates, belonging to the field of chemical preparation. The preparation method includes the following steps: dissolving 3,3-dimethyl-2-benzofuran-1(3H)-one in an organic solvent, adding a catalyst and heating the reaction, followed by purification after the reaction to obtain 10,10-dimethylanthrone. The catalyst includes at least one selected from ferric chloride, ferrous chloride, zinc chloride, and anhydrous aluminum trichloride; the organic solvent includes benzene. This preparation method has not been reported in the literature, significantly shortens the process flow for synthesizing melitracen intermediates, avoids the use of concentrated sulfuric acid, reduces waste, and saves costs.

The invention belongs to the technical field of medicines, and particularly relates to an esketamine and mirtazapine synergistic antidepressant pharmaceutical composition and application thereof. The antidepressant pharmaceutical composition comprises the following active components: esketamine and mirtazapine, the esketamine is an N-methyl-D-aspartic acid receptor antagonist, and the mirtazapine is an adrenergic alpha2-AR antagonist. According to the anti-depression pharmaceutical composition containing esketamine and mirtazapine, through the synergistic effect of esketamine and mirtazapine, the effects of reducing dosage, prolonging aging and reducing adverse reactions are achieved, and major depressive disorder is safely and effectively prevented and treated.

The invention provides a novel mirtazapine external liposome ointment for cats and a preparation method of the novel mirtazapine external liposome ointment. The novel mirtazapine external liposome ointment is prepared by mixing mirtazapine liposome and an ointment matrix, the mirtazapine liposome comprises the following components in percentage by weight: 1.0%-3.0% of mirtazapine, 10.0%-25% of a solvent, 1.0%-15.0% of phospholipid, 0.5%-5.0% of cholesterol and 0.3%-2.0% of a membrane stabilizer, the ointment matrix comprises 0.3%-2.0% of an antioxidant, an excipient and 5.0%-15.0% of a penetration enhancer; the liposome is used as a carrier, so that the miazapine can be effectively promoted to penetrate through the skin barrier of cats, the transdermal absorption rate of the medicine is increased, the concentration of the medicine is remarkably increased, the treatment effect is enhanced, the anorexia symptom of the cats can be effectively improved, and the problem of weight loss can be relieved; the liposome has a long-acting slow-release effect, and can form a drug storage cavern in vivo, slowly release drugs, prolong the action time and reduce the medication frequency. The preparation can maintain the stable and effective blood concentration for 24 hours, can realize the administration frequency once a day or once an alternate day, and reduces the administration burden of an owner.

The present disclosure provides pharmaceutical compositions and methods for the treatment of a sleep disorder such as insomnia, by inducing, extending, or consolidating sleep. The compositions comprise mirtazapine, or a salt or derivative thereof, optionally in combination with and gabapentin, or a salt or derivative thereof, at relatively low doses of each such that the combination provides useful therapeutic benefit while avoiding unwanted side effects associated with treatment using alternative pharmaceutical agents.

The utility model discloses mirtazapine tablet preparation equipment which comprises a shell, a supporting column is fixedly connected to the inner wall of the bottom of the shell, a rotating frame is arranged at the top of the supporting column, a power assembly is arranged between the supporting column and the rotating frame to enable the rotating frame to rotate, and a discharging assembly is arranged at one end of the rotating frame. The other end of the rotating frame is provided with a pressing assembly used for pressing tablets, the top of the shell is provided with a plurality of sets of evenly-distributed finished product openings, ejection assemblies used for pushing out the tablets are arranged in the finished product openings, and the top of the shell is provided with a plurality of discharging openings corresponding to the finished product openings in a one-to-one mode. Tablets do not need to be sucked out through a suction pump, residual medicine powder is prevented from entering the suction pump to cause damage to the suction pump, cost is saved, the tablets formed through pressing can be conveniently discharged, time is saved, efficiency is improved, acting force borne by the tablets during falling can be reduced, the tablets are prevented from being dispersed, and the service life of the tablets is prolonged. And the use effect of the flaking equipment is improved.

The present disclosure provides pharmaceutical compositions and methods for the treatment of a sleep disorder such as insomnia, by inducing, extending, or consolidating sleep. The compositions comprise mirtazapine, or a salt or derivative thereof, optionally in combination with and gabapentin, or a salt or derivative thereof, at relatively low doses of each such that the combination provides useful therapeutic benefit while avoiding unwanted side effects associated with treatment using alternative pharmaceutical agents.

Pharmaceutical compositions and methods for treating organ fibrosis related diseases, the pharmaceutical compositions and methods comprising mirtazapine or a pharmaceutically acceptable salt thereof or a combination of mirtazapine or a pharmaceutically acceptable salt thereof and narcotine or a pharmaceutically acceptable salt thereof, the compounds can effectively inhibit the organ fibrosis lesion of a patient so as to treat organ fibrosis related diseases.

The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of mirtazapine in preparation of a medicine for enhancing the tumor treatment effect of adriamycin. Research results of the invention show that MALS3 up-regulating agent mirtazapine can enhance the therapeutic effect of chemotherapeutic drug adriamycin in inhibiting tumor growth.